SCHEMBL5947768

SCHEMBL5947768

FC(F)(F)c1cccc(Oc2cccc(CNCCc3cccc(Cl)c3)c2)c1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.59
▸ MEN1 O00255 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ CYP1A2 P05177 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2D6 P10635 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.49
▸ CHRM2 P08172 1/20 0.48
▸ ROCK1 Q13464 1/20 0.47
▸ CNR1 P21554 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ BCHE P06276 2/20 0.45
▸ SCN8A Q9UQD0 1/20 0.45
▸ ADRB3 P13945 3/20 0.44
▸ ADRB1 P08588 1/20 0.44
▸ FDFT1 P37268 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5947704 0.86 KDM4E (0.69) KDM4EMEN1KMT2ACYP1A2CYP3A4
SCHEMBL5947283 0.85 BCHE (0.58) KDM4EMEN1KMT2ACYP1A2CYP3A4
SCHEMBL5947369 0.84 KDM4E (0.64) KDM4EMEN1KMT2ATDP1ROCK1
SCHEMBL5947594 0.84 CYP1A2 (0.64) CYP1A2CYP3A4CYP2D6CYP2C19CHRM2
SCHEMBL5947523 0.84 CYP1A2 (0.56) KDM4ECYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL5947135 0.84 CYP1A2 (0.56) CYP1A2CYP3A4CYP2D6CYP2C19CHRM2
SCHEMBL5947469 0.83 KDM4E (0.62) KDM4EMEN1KMT2ACYP1A2CYP3A4
SCHEMBL5947672 0.83 CYP1A2 (0.70) KDM4ECYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL5947090 0.82 CYP1A2 (0.49) KDM4EMEN1KMT2ACYP1A2CYP3A4
SCHEMBL5947251 0.82 KDM4E (0.61) KDM4EMEN1KMT2ATDP1ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US claimed
CN-1610547-A N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor LILLY CO ELI (US) 2005-04-27 — — CN claimed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP claimed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B KDM4E 1970/4885MEN1 1889/4885KMT2A 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback